Personal Genome Diagnostics Inc.
BALTIMORE, MD · Founded 2010 · CIK 0001530958 · Medtech · Acquired
Circulating tumor DNA (ctDNA) assay for microsatellite instability detection in plasma
personalgenome.com →- Grants
- $1.7M
- 7 awards
- Sector median: 1
- Raised
- $198M
- 8 Form D · Feb 2021
- 67 months since last filing
- Contracts
- $7.9M
- 18 awards · Veterans Affairs, Health and Human S
- #84 of 4531 in medtech
- Patents
- 25
- 2 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201120132015201720192021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $2,000,000 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Healthca | $189,000 | |
| Private capital raised | Form D · SEC | $4,322,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Detection of Minimal Residual Disease through Analysis of Genetic Alterations in the Circulation of Stage II Colorectal Cancer Patients | $216,858 | |
| Federal grant | Department of Health and Human Services · Phase I · Detection of Minimal Residual Disease through Analysis of Genetic Alterations in the Circulation of Stage II Colorectal Cancer Patients | $216,858 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Non-Invasive Plasma-Based Test to Stratify Lung Cancer Patients for Targeted Therapies | $214,379 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Non-Invasive Plasma-Based Test to Stratify Lung Cancer Patients for Targeted Therapies | $214,379 | |
| Private capital raised | Form D · SEC | $20,451,998 | |
| Federal contract | Department of Veterans Affairs · Task Order For Second Ordering Period Igf::ot::igf | $49,838 | |
| Federal contract | Department of Health and Human Services · Drugs And Biologicals | $6,500 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Heal | $72,481 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Heal | $98,925 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf SBIR Phase I Topic 354- A Non-invasive Approach To Assess Mutation Load In Tumors For Treatment With Checkpoint Inhibitors | $222,994 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Heal | $437,100 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Heal | $147,900 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf P00001 Accession 64 Gene Plasmid Assay, Plasmaselect; Modify And Supplement Distribution Of Clinical Reports And Clarify File Format Types. P00001. The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - US | $349,600 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf Genomic Analysis Of Cancerous Tumor Tissue | $449,600 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel, Plasma-Based Microsatellite Instability Diagnostic for Guiding Immunotherapy | $297,850 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel Plasma Based Microsatellite Instability Diagnostic for Guiding Immunotherapy | $297,850 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf Genomic Analysis Of Cancerous Tumor Tissue | $313,025 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf Oncology Testing Services | $3,627,950 | |
| Private capital raised | Form D · SEC | $65,367,412 | |
| Federal contract | Department of Veterans Affairs · Igf::ot::igf Oncology Testing Services | $123,550 | |
| Federal contract | Department of Veterans Affairs · Genomic Testing Services | $1,805,400 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Federal contract | Department of Veterans Affairs · Ratification Of Unauthorized Commitment Dna Testing | $21,000 | |
| Federal contract· 1 of 3 same day | Department of Veterans Affairs · Uac - Molecular Tissue Testing | $1,990 | |
| Federal contract· 2 of 3 same day | Department of Veterans Affairs · Uac - Molecular Tissue Testing | $1,990 | |
| Federal contract· 3 of 3 same day | Department of Veterans Affairs · Uac Molecular Tissue Testing | $1,990 | |
| Private capital raised | Form D · SEC | $2,750,000 | |
| Private capital raised | Form D · SEC | $97,729,418 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 81 | Aethlon Medical, Inc. | $8.1M | $22M |
| 82 | LIFEWARE LABS LLC | $8.1M | — |
| 83 | QUADRIDOX INC. | $8.0M | — |
| 84 | Personal Genome Diagnostics Inc. | $7.9M | $198M |
| 85 | TAO TREASURES, LLC | $7.7M | — |
| 86 | OASIS DIAGNOSTICS CORPORATION | $7.7M | — |
| 87 | SOTERIX MEDICAL, INC. | $7.6M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Sam AngiuoliExecutive Officer
- Sam AnguioliExecutive Officer
- Samuel AnguioliExecutive Officer
- Megan BaileyDirector · Executive Officer
- Jeff BoschwitzExecutive Officer
- Cindy CaccuroExecutive Officer
- Jack CrowleyDirector · Executive Officer
- Felix DawsonDirector
- Luis DiazExecutive Officer
- Luis Diaz, Jr.Director · Executive Officer · Promoter
- Jason FullerDirector
- Scott GotshallExecutive Officer
- Sian JonesExecutive Officer
- Lisa KannExecutive Officer
- Kenneth KinzlerPromoter
- Justin KleinDirector
- James LaFranceDirector
- Lily LiDirector
- Anthony NewtonExecutive Officer
- Garry NicholsonDirector
- Kavita PatelDirector
- Kevin ReidyDirector
- Mark SausenExecutive Officer
- William StevensExecutive Officer
- Victor VelculescuDirector · Executive Officer · Promoter
- Bert VogelsteinPromoter
- Douglas WardDirector · Executive Officer
Patents
- Compositions and Methods for Nucleic Acid Quality Determinationgranted
- Qualification Of Sequencing Instruments And Reagents For Use In Molecular Diagnostic Methodsapplication
- Method Of Improving Prediction Of Response For Cancer Patients Treated With Immunotherapyapplication
- Methods And Systems For Developing Personalized Vaccine By Identification And Prioritization Of Mutation-derived Neoantigensapplication
- Systems And Methods For Analyzing Nucleic Acidapplication
- Non-unique Barcodes In A Genotyping Assayapplication
- Cancer Detection Through Integrated Analysis Of Whole Genome Sequencingapplication
- Selective Capture of Target DNA Sequencesapplication
- Microsatellite Instability Signaturesapplication
- Process for Microsatellite Instability Detectionapplication
- Selective Capture Of Target Dna Sequencesgranted
- Floating Barcodesapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.